SpyGlass Pharma, Inc.

What they do

Its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), consists of proprietary drug pads attached to an intraocular lens and is designed to be implanted during routine cataract surgery to deliver three years of bimatoprost and reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing a non-IOL-based, ring-shaped, sustained-release bimatoprost implant (BIM-DRS) for standalone implantation, retreatment, and pseudophakic patients. It has no commercial products and generates no product revenue; operations are funded by equity capital.

Revenue drivers

• BIM-IOL System — Lead product candidate; no revenue today. Designed to be implanted during routine cataract surgery to deliver three years of bimatoprost for OAG or OHT; the company cites approximately one million annual cataract procedures in glaucoma and ocular hypertension patients as the potential addressable base if approved.
• BIM-DRS (Bimatoprost Drug Ring System) — Second product candidate; no revenue today. Non-bioerodible ring-shaped implant designed to deliver at least three years of bimatoprost, aimed at standalone procedures, retreatment of BIM-IOL patients, and pseudophakic patients.
• Reimbursement pathway (not a revenue line) — In May 2026 the AMA CPT Editorial Panel approved a new add-on Category III CPT code (+1090T), released to the AMA website July 1, 2026, for use with established Category I codes such as 66984 and 66991; the company believes this could accelerate commercial adoption of the BIM-IOL System if approved.

Recent performance

For the second quarter of 2026, net loss was $19.9 million, or ($0.59) per basic and diluted share, versus $8.7 million, or ($3.81) per share, in the second quarter of 2025. Research and development expenses rose to $10.9 million from $7.3 million, primarily due to hiring of clinical personnel, and general and administrative expenses rose to $11.0 million from $2.0 million, primarily due to higher professional service fees and personnel costs. Cash, cash equivalents and short-term investments totaled $234.2 million as of June 30, 2026. Full-year 2025 net loss was $39.9 million versus $29.2 million in 2024, with operating cash flow of negative $32.7 million in 2025 and negative $22.0 million in 2024. The latest balance sheet showed total assets of $243.4 million, total liabilities of $11.1 million, and shareholder equity of $232.4 million as of June 30, 2026.

Strategy

The company is running two registrational Phase 3 trials of the BIM-IOL System at the intended 78 mcg commercial dose, each expected to enroll approximately 400 patients across 45 sites, with enrollment completion expected in 2027 and, pending successful results, a planned 505(b)(2) NDA submission in 2028. It plans to initiate a single-site first-in-human trial of the BIM-DRS in the second half of 2026. It is building commercial and reimbursement groundwork, including the new add-on CPT code and the June 2026 appointment of Mike Pinder as Vice President, Marketing, and is engaging cataract and glaucoma surgeons at medical meetings. The company states its cash, cash equivalents and short-term investments are expected to fund planned operations through 2028.

Risks

• No approved products or revenue — The company has no products approved for commercial sale and has incurred significant losses and negative cash flows from operations since formation.
• Clinical and regulatory uncertainty — The BIM-IOL System and BIM-DRS depend on clinical trials demonstrating safety and efficacy, and the company states there is no guarantee its trials will produce positive results, be consistent with past results, or lead to FDA approval.
• Reliance on third parties — The company relies on third parties to conduct clinical trials and to manufacture its product candidates for clinical trials and potential commercialization.
• License and intellectual property — The company must maintain compliance with its license agreement with the Regents of the University of Colorado, including development and commercial milestones, and its intellectual property position depends on the scope of protection it can establish and maintain.

Outlook

Management says enrollment in the two Phase 3 BIM-IOL System trials remains on track for completion in 2027, with four-year efficacy and safety follow-up data expected in the fourth quarter of 2026. The BIM-DRS first-in-human trial is on track to start in the second half of 2026. The company expects its $234.2 million in cash, cash equivalents and short-term investments as of June 30, 2026 to fund planned operations through 2028.